Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

11/7/2017, Tuesday

Media Contacts:
Teresa Panas
BioComm Network, on behalf of Bausch + Lomb
(973) 809-8590 or


  • Attendees Can Experience the Effects of AMD Through Patients’ Eyes
  • “Test Drive” Newly Enhanced VICTUS® Femtosecond Laser Platform with 3.3 Software,
    Stellaris Elite™ Vision Enhancement System featuring the Vitesse™ Hypersonic Vitrectomy System, and Next-Generation enVista® MX60E IOL
  • Engage with a Virtual Glaucoma “Patient” to Learn More About VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%)

BRIDGEWATER, NJ, Nov. 7, 2017 – Bausch + Lomb, a leading global eye health company, today announced that it will feature three interactive exhibits during the Annual Meeting of the American Academy of Ophthalmology (AAO) at the Ernest N. Morial Convention Center in New Orleans, LA (Nov. 11-14), offering attendees the opportunity to gain hands-on experience with its latest innovations and enhance their understanding of the patient journey.

These exhibits featured at the Bausch + Lomb Booth (#2323) will include:

  • An interactive virtual reality simulation which “shows” the AMD patient’s view;
  • An augmented reality experience about the glaucoma patient journey, allowing attendees to learn more about VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%);
  • A “test drive” experience allowing surgeons to try the company’s latest surgical technologies including the newly enhanced VICTUS® femtosecond laser platform with 3.3 software, Stellaris Elite™ featuring the Vitesse™ hypersonic vitrectomy system with patented technology and Bi-Blade® vitrectomy cutter, and the next-generation enVista® MX60E IOL with StableFlex™ technology.

“We’ve designed these unique experiences to provide customers with a more impactful way to gain insight into these diseases and how they affect their patients, as well as to learn more about the benefits of our latest innovations first-hand,” said Tracy Valorie, senior vice president, Ophthalmology Rx and Surgical, Bausch + Lomb. “We’re confident that when attendees visit our booth, they will walk away with a new perspective on how Bausch + Lomb can help them advance their practices and better serve their patients.”

Interactive Virtual Reality Simulation “Shows” the AMD Patient’s View
For the first time at AAO-Ophthalmology, Bausch + Lomb will present its Age-Related Macular Degeneration (AMD) Virtual Experience, allowing meeting attendees to experience the daily challenges this condition brings their patients with mild to more advanced stages of AMD using state-of-the-art virtual reality technology. A progressive eye disease, AMD affects an estimated nine million people, and is a leading cause of vision loss in people age 50 and older. AAO attendees are invited to experience the virtual reality tool by visiting the Bausch + Lomb booth (#2323) at any time during the meeting.

In Booth Wet-Lab Features New Surgical Technologies
Surgeons are invited to “test drive” several new surgical technologies during 30-minute interactive wet lab sessions in the Bausch + Lomb booth during the AAO meeting. These technologies include the VICTUS® femtosecond laser with 3.3 software, which features a new option for capsulotomy and lens fragmentation centration, providing surgeons with the choice to center the procedure on the pupil, the limbus, the lens apex or other positions as defined by the surgeon. Another feature of the new software is the introduction of the grid lens fragmentation pattern that provides additional options for surgeons to optimize their individual phacoemulsification technique. The Stellaris Elite™ vision enhancement system continues to expand surgeon’s capabilities with new Adaptive Fluidics™ packs for cataract removal. This platform, also recently released for retina surgery, offers a cutting edge, dual-port illumination system, Bi-Blade® vitrectomy cutter that offers effective cut rates up to 15,000 cuts per minute (cpm), and the novel Vitesse™ hypersonic vitrectomy system. Vitesse™ is the first and only hypersonic, 100% open port vitrectomy platform, representing a revolutionary new approach to vitreous removal by eliminating the need for pneumatic guillotine cutting. Both the Stellaris Elite™ and Vitesse™ will be available as part of the wet lab. In addition, attendees will also have an opportunity to implant the company’s enVista® MX60E IOL with StableFlex™ technology. This lens is the next-generation of Bausch + Lomb's hydrophobic acrylic lens, which provides improved material properties to enhance optic recovery following delivery. To schedule an appointment to try these new technologies in the wet lab during the meeting, visit:

Augmented Reality Experience Highlights Glaucoma Patient Experience and New VYZULTA™
Attendees are invited to learn more about new VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) in the Bausch + Lomb booth through an augmented reality experience via a life-sized, 3D patient named “Vinny”. Participants will have the opportunity to interact with and hear Vinny’s story as a patient who was recently diagnosed with glaucoma. By activating several ‘hot spots’ on the application, attendees can learn more about VYZULTA™, the treatment option Vinny’s eye care professional prescribed, including the product’s dual mechanism of action, molecule structure, and supporting clinical studies. VYZULTA™ recently received U.S. Food and Drug Administration (FDA) approval as the first prostaglandin analog with one of its metabolites being nitric oxide (NO) indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.1

In addition to interacting with Vinny, attendees can play two interactive touch screen games. The first, Test Your Glaucoma Knowledge, will quiz users on glaucoma statistics. The second, Dual Pathways Challenge, will instruct players to guide the VYZULTA molecule’s two moieties through the appropriate outflow pathways; the uveoscleral pathway and the trabecular meshwork. Those who score the highest throughout the meeting in each game will be listed as top players on a digital-displayed leaderboard in the Bausch + Lomb booth.

Featured Bausch + Lomb Products
In addition to these interactive exhibits, the Bausch + Lomb booth will feature the latest additions to the Bausch + Lomb Synergetics retina surgery instrument line, which now offers a compendium of 27-gauge accessories and a new series of Storz® ophthalmic instruments for tight clearance cataract surgery under the microscope with aberrometers. Products from the company’s pharmaceuticals and over-the-counter vitamin supplements portfolios will also be showcased.


Friday, Nov. 10

Vitreoretinal surgeons are invited to “The Retina Sessions”, an educational event sponsored by
Bausch + Lomb, on Friday, Nov. 10 from 7–10 p.m. at the Ogden Museum of Southern Art, Patrick F. Taylor Library (925 Camp Street, New Orleans, LA 70130). Attendees will join a panel of experts in a lively discussion as they analyze and provide insights to challenging retinal cases, some of which will involve the use of the Stellaris Elite™ and the Vitesse™ hypersonic vitrectomy system. The featured panel of experts will include Kevin J. Blinder, M.D.; Sunir J. Garg, M.D.; Gaurav K. Shah, M.D.; Sunil Srivastava, M.D.; and Asheesh Tewari, M.D. Attendees can register in advance at  

On Friday, Nov. 10, meeting attendees are also invited to join an evening of discussion and best practice sharing on IOLs, “Delivering Innovation for Excellent Outcomes and Efficiency”, from 7 – 10 pm, at Tableau Restaurant (616 St. Peter Street, New Orleans, LA 70116). Registrations are required for this event. Attendees can register here.

Saturday, Nov. 11
Engage in dynamic conversation during the complex case management series, “Mission Possible”, on Saturday, Nov. 11 at the Ogden Museum of Southern Art (925 Camp Street, New Orleans, LA 70130). Attendees are asked to register in advance here.

Sunday, Nov. 12

Learn more about the Bausch + Lomb VICTUS® femtosecond laser during the “VICTUS® Users Event” on Sunday, Nov. 12 from 6-8 p.m. at the Court of Two Sisters, Grand Marquis Room (613 Royal Street, New Orleans, LA 70130). Registrations are required for this event, by registering here.

Run/Walk for Vision to Support Eye Tissue Donation
Proudly supported by Bausch + Lomb, the 32nd annual Run for Vision, a 5k benefit run/walk, will begin and finish at the New Orleans RiverWalk at Canal Street and Convention Center Drive on Sunday, Nov. 12 at 6:30 a.m. CST to help raise awareness and support of eye tissue donation on behalf of the Eye Bank Association of America (EBAA). Pre-registered runners and walkers can pick up their race packets, which include runner bib and technical running t-shirt, at the Bausch + Lomb booth (#2323) between 9 a.m. and 5 p.m. CST on Saturday, Nov. 11. Non-registered attendees can sign up to participate in the race in the Bausch + Lomb booth or online here.

Scientific Podium Presentations and Posters

The following posters will feature Bausch + Lomb’s surgical technologies during the meeting on Sunday, Nov. 12:

  • Liang, Eva. “Comparison of Several IOL Power Calculation Formulae with Intraoperative Aberrometry for an Accommodative IOL.” Sunday, Nov. 12 from 12:45-1:45 p.m.; Ernest N. Morial Convention Center, Hall C.
  • Liang, Eva. “Comparison of Visual Outcomes of an Accommodative IOL and an Extended Depth of Focus IOL.” Sunday, Nov. 12 from 12:45-1:45 p.m.; Ernest N. Morial Convention Center, Hall C.

Indication and Important Safety Information about VYZULTA

VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024%, is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

1. Vyzulta™ [prescribing information]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2017.

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates except Bi-Blade is a trademark of Medical Instrument Development Laboratories, Inc. Any other product/brand names are trademarks of the respective owners.
© 2017 Bausch & Lomb Incorporated. MTB.0153.USA.17


Number of views (2151)/Comments (0)